|
MX344559B
(es)
|
2008-04-29 |
2016-12-20 |
Ascendis Pharma As |
Compuestos de hormona de crecimiento humana recombinante unidos al peg.
|
|
MX337432B
(es)
|
2009-12-15 |
2016-03-04 |
Ascendis Pharma As |
Composicion de la hormona del crecimiento seca enlazada transitoriamente a un portador del polimero.
|
|
US9221882B2
(en)
|
2010-05-21 |
2015-12-29 |
Technische Universitat Munchen |
Biosynthetic proline/alanine random coil polypeptides and their uses
|
|
AU2012296951B2
(en)
*
|
2011-08-12 |
2016-09-15 |
Ascendis Pharma A/S |
Protein carrier-linked prodrugs
|
|
JP6355563B2
(ja)
*
|
2012-02-27 |
2018-07-11 |
アムニクス オペレーティング インコーポレイテッド |
Ｘｔｅｎ共役組成物およびそれを製造する方法
|
|
CN108686203A
(zh)
|
2012-04-04 |
2018-10-23 |
哈洛齐梅公司 |
使用抗透明质酸剂和肿瘤靶向紫杉烷的组合疗法
|
|
WO2014114660A1
(en)
*
|
2013-01-22 |
2014-07-31 |
Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) |
Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion
|
|
JP6259208B2
(ja)
*
|
2013-06-17 |
2018-01-10 |
雪印メグミルク株式会社 |
ヒアルロン酸産生促進剤
|
|
JP6259207B2
(ja)
*
|
2013-06-17 |
2018-01-10 |
雪印メグミルク株式会社 |
エラスチン産生促進剤
|
|
JP6259209B2
(ja)
*
|
2013-06-17 |
2018-01-10 |
雪印メグミルク株式会社 |
コラーゲン産生促進剤
|
|
EP3068438A1
(en)
|
2013-11-11 |
2016-09-21 |
Ascendis Pharma Relaxin Division A/S |
Relaxin prodrugs
|
|
US9618507B2
(en)
|
2014-02-24 |
2017-04-11 |
Betanien Hospital |
Methods of treating rheumatoid arthritis
|
|
WO2015132004A1
(en)
|
2014-03-05 |
2015-09-11 |
Merz Pharma Gmbh & Co. Kgaa |
Novel recombinant clostridial neurotoxins with increased duration of effect
|
|
PL228341B1
(pl)
*
|
2014-04-21 |
2018-03-30 |
Bio Ventures Inst Spolka Z Ograniczona Odpowiedzialnoscia |
Sposób uzyskiwania białka poliepitopowego oraz wektor DNA do realizacji tego sposobu
|
|
US10821152B2
(en)
|
2014-08-26 |
2020-11-03 |
Betanien Hospital |
Methods, agents and compositions for treatment of inflammatory conditions
|
|
SG11201703870UA
(en)
|
2014-11-18 |
2017-06-29 |
Ascendis Pharma Endocrinology Div As |
Novel polymeric hgh prodrugs
|
|
PT3220892T
(pt)
|
2014-11-21 |
2021-11-05 |
Ascendis Pharma Endocrinology Div A/S |
Formas de dosagem de hormona do crescimento de longa ação
|
|
ES2784603T3
(es)
|
2015-06-02 |
2020-09-29 |
Novo Nordisk As |
Insulinas con extensiones recombinantes polares
|
|
TW201718627A
(zh)
|
2015-06-11 |
2017-06-01 |
梅茲製藥有限兩合公司 |
重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
|
|
EP3347874B1
(en)
*
|
2015-09-09 |
2021-05-12 |
Technische Universiteit Eindhoven |
Imaging of dispersion and velocity of contrast agents
|
|
EP3355931B1
(en)
|
2015-10-01 |
2024-06-26 |
Novo Nordisk A/S |
Protein conjugates
|
|
EP4491735A3
(en)
*
|
2015-10-08 |
2025-04-16 |
The Governors of the University of Alberta |
Hepatitis c virus e1/e2 heterodimers and methods of producing same
|
|
WO2017109087A1
(en)
*
|
2015-12-22 |
2017-06-29 |
Xl-Protein Gmbh |
Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences
|
|
CN108697768B
(zh)
|
2015-12-23 |
2022-07-22 |
约翰霍普金斯大学 |
长效glp-1r激动剂作为神经系统病状和神经退行性病状的治疗方法
|
|
IL259827B2
(en)
|
2016-01-08 |
2025-07-01 |
Ascendis Pharma Growth Disorders As |
Controlled-release CNP agonists with low initial NPR-B activity
|
|
CA3007976C
(en)
|
2016-01-08 |
2023-09-26 |
Ascendis Pharma Growth Disorders A/S |
Cnp prodrugs with large carrier moieties
|
|
EP3400021A1
(en)
|
2016-01-08 |
2018-11-14 |
Ascendis Pharma Growth Disorders A/S |
Controlled-release cnp agonists with low npr-c binding
|
|
DK3400019T3
(da)
|
2016-01-08 |
2022-10-24 |
Ascendis Pharma Growth Disorders As |
CNP-prodrugs med bærerbinding ved ringenheden
|
|
ES3064816T3
(en)
|
2016-01-08 |
2026-04-29 |
Ascendis Pharma Growth Disorders As |
Controlled-release cnp agonists with reduced side-effects
|
|
WO2017118700A1
(en)
|
2016-01-08 |
2017-07-13 |
Ascendis Pharma Growth Disorders A/S |
Controlled-release cnp agonists with increased nep stability
|
|
US11078472B2
(en)
|
2016-01-20 |
2021-08-03 |
Merz Pharma Gmbh & Co., Kgaa |
Recombinant clostridial neurotoxins with increased duration of effect
|
|
MY208384A
(en)
|
2016-03-01 |
2025-05-05 |
Ascendis Pharma Bone Diseases As |
Pth prodrugs
|
|
CN108463242A
(zh)
|
2016-03-02 |
2018-08-28 |
梅尔兹制药公司 |
包含肉毒杆菌毒素的组合物
|
|
US11306130B2
(en)
|
2016-04-01 |
2022-04-19 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
PAR3 mimetic peptides and uses thereof
|
|
US11813336B2
(en)
*
|
2016-05-04 |
2023-11-14 |
Navigo Proteins Gmbh |
Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
|
|
US11896671B2
(en)
|
2016-07-13 |
2024-02-13 |
Ascendis Pharma A/S |
Conjugation method for carrier-linked prodrugs
|
|
US11564974B2
(en)
|
2016-09-29 |
2023-01-31 |
Ascendis Pharma Growth Disorders A/S |
Combination therapy with controlled-release CNP agonists
|
|
KR102627405B1
(ko)
|
2016-09-29 |
2024-01-18 |
아센디스 파마 본 디지즈 에이/에스 |
조절 방출 pth 화합물을 위한 투여 용법
|
|
US12453778B2
(en)
|
2016-09-29 |
2025-10-28 |
Ascendis Pharma Bone Diseases A/S |
Incremental dose finding in controlled-release PTH compounds
|
|
HRP20230383T1
(hr)
|
2016-09-29 |
2023-07-07 |
Ascendis Pharma Bone Diseases A/S |
Pth spojevi s malim omjerima maksimalne prema minimalnoj koncentraciji
|
|
US10738338B2
(en)
|
2016-10-18 |
2020-08-11 |
The Research Foundation for the State University |
Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
|
|
US11807671B2
(en)
*
|
2016-11-16 |
2023-11-07 |
Auckland Uniservices Limited |
Methods for protein ligation and uses thereof
|
|
JP2020513019A
(ja)
|
2017-04-05 |
2020-04-30 |
ノヴォ ノルディスク アー／エス |
オリゴマー伸長インスリン−Ｆｃコンジュゲート
|
|
WO2018233813A1
(en)
|
2017-06-20 |
2018-12-27 |
Merz Pharma Gmbh & Co. Kgaa |
NOVEL RECOMBINANT BOTULINUM TOXINS WITH INCREASED DURATION
|
|
US10174302B1
(en)
|
2017-06-21 |
2019-01-08 |
Xl-Protein Gmbh |
Modified L-asparaginase
|
|
CN110891612A
(zh)
*
|
2017-06-21 |
2020-03-17 |
Xl-蛋白有限责任公司 |
蛋白质药物与p/a肽的缀合物
|
|
SG11201912625QA
(en)
|
2017-06-21 |
2020-01-30 |
Jazz Pharmaceuticals Ireland Ltd |
Modified l-asparaginase
|
|
EP3418383A1
(en)
|
2017-06-21 |
2018-12-26 |
XL-protein GmbH |
Modified l-asparaginase
|
|
EP3649143B1
(en)
|
2017-07-06 |
2022-08-31 |
Merz Pharma GmbH & Co. KGaA |
Novel recombinant botulinum neurotoxins with increased duration of effect
|
|
EP3483619A1
(en)
*
|
2017-11-13 |
2019-05-15 |
Technische Universität München |
Automated noninvasive determining the sex of an embryo of and the fertility of a bird's egg
|
|
US20200354706A1
(en)
*
|
2017-11-22 |
2020-11-12 |
Merz Pharma Gmbh & Co. Kgaa |
Novel recombinant botulinum toxin with increased duration of effect
|
|
US20190184028A1
(en)
*
|
2017-12-14 |
2019-06-20 |
Janssen Biotech, Inc. |
Targeting with firbronectin type iii like domain molecules
|
|
GB201804092D0
(en)
*
|
2018-03-14 |
2018-04-25 |
Imperial Innovations Ltd |
Methods and compositions
|
|
CN111918665B
(zh)
|
2018-03-28 |
2024-11-26 |
阿森迪斯药物肿瘤股份有限公司 |
Il-2缀合物
|
|
AU2019246390B2
(en)
|
2018-03-28 |
2025-03-27 |
Ascendis Pharma A/S |
Conjugates
|
|
TWI724392B
(zh)
*
|
2018-04-06 |
2021-04-11 |
美商美國禮來大藥廠 |
生長分化因子15促效劑化合物及其使用方法
|
|
CN112334152A
(zh)
|
2018-05-18 |
2021-02-05 |
阿森迪斯药物骨疾病股份有限公司 |
Pth缀合物的起始剂量
|
|
CN119264211A
(zh)
|
2018-08-27 |
2025-01-07 |
瑞泽恩制药公司 |
拉曼光谱在下游纯化中的应用
|
|
US20220002370A1
(en)
|
2018-09-27 |
2022-01-06 |
Xilio Development, Inc. |
Masked cytokine polypeptides
|
|
CN111153965A
(zh)
*
|
2018-11-07 |
2020-05-15 |
浙江道尔生物科技有限公司 |
用于改善活性蛋白或多肽性能的人工重组蛋白及其应用
|
|
EP3887393A1
(en)
|
2018-11-26 |
2021-10-06 |
Novartis AG |
Lpl-gpihbp1 fusion polypeptides
|
|
US20240018190A1
(en)
*
|
2019-01-10 |
2024-01-18 |
Roswell Biotechnologies, Inc. |
Conductive synthetic peptides for molecular electronics
|
|
MY209748A
(en)
|
2019-02-11 |
2025-07-31 |
Ascendis Pharma Bone Diseases As |
Liquid pharmaceutical formulations of pth conjugates
|
|
MX2021008708A
(es)
|
2019-02-11 |
2021-09-21 |
Ascendis Pharma Growth Disorders As |
Formulaciones farmaceuticas secas de conjugados de peptido natriuretico tipo c (cnp).
|
|
AU2020233198B2
(en)
|
2019-03-04 |
2025-05-15 |
Ascendis Pharma Endocrinology Division A/S |
Long-acting growth hormone dosage forms with superior efficacy to daily somatropin
|
|
EP3714909A1
(en)
*
|
2019-03-28 |
2020-09-30 |
Industrie Biomediche Insubri S.A. |
Improved bone implant matrix comprising proline-rich peptide and method of preparing the same
|
|
US10784093B1
(en)
*
|
2019-04-04 |
2020-09-22 |
Thermo Finnigan Llc |
Chunking algorithm for processing long scan data from a sequence of mass spectrometry ion images
|
|
WO2020254603A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma A/S |
CONJUGATES OF π-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS
|
|
AU2020296297B2
(en)
|
2019-06-21 |
2025-06-12 |
Ascendis Pharma A/S |
Conjugates of heteroaromatic nitrogen-comprising compounds
|
|
US20220304993A1
(en)
|
2019-06-21 |
2022-09-29 |
Ascendis Pharma A/S |
Conjugates of an electron-donating nitrogen or tertiary amine comprising compounds
|
|
AU2020338947A1
(en)
|
2019-08-27 |
2022-03-31 |
Tonix Pharma Limited |
Modified TFF2 polypeptides
|
|
CA3156066A1
(en)
|
2019-10-25 |
2021-04-29 |
Mi Rim Choi |
Recombinant l-asparaginase
|
|
WO2021113434A1
(en)
*
|
2019-12-03 |
2021-06-10 |
Rodan & Fields, Llc |
Peptides and compositions for inhibiting hair growth
|
|
US20230242655A1
(en)
|
2019-12-03 |
2023-08-03 |
Evotec International Gmbh |
Interferon-associated antigen binding proteins and uses thereof
|
|
EP4071178A4
(en)
*
|
2019-12-06 |
2024-10-09 |
Ajinomoto Co., Inc. |
METHOD FOR PREPARING A PEPTIDE WITH PHYSIOLOGICAL ACTIVITY AND A PEPTIDE WITH A SHORT LINKER
|
|
JP7851853B2
(ja)
|
2020-01-03 |
2026-04-27 |
アセンディス ファーマ エー／エス |
分子内転位を受けるコンジュゲート
|
|
MX2022007371A
(es)
|
2020-01-13 |
2022-07-12 |
Ascendis Pharma Bone Diseases As |
Tratamiento del hipoparatiroidismo.
|
|
CN113527485B
(zh)
*
|
2020-04-17 |
2024-11-15 |
湖南麦济生物技术股份有限公司 |
抗人白细胞介素-4受体α抗体及其制备方法和应用
|
|
GB202007106D0
(en)
*
|
2020-05-14 |
2020-07-01 |
Ucl Business Plc |
Cyclosporine analogues
|
|
KR20230019889A
(ko)
|
2020-06-03 |
2023-02-09 |
아센디스 파마 온콜로지 디비전 에이/에스 |
Il-2 서열 및 이의 용도
|
|
WO2022029178A1
(en)
|
2020-08-05 |
2022-02-10 |
Ascendis Pharma A/S |
Conjugates comprising reversible linkers and uses thereof
|
|
CA3192744A1
(en)
|
2020-09-23 |
2022-03-31 |
Oskar SMRZKA |
Compound for the sequestration of undesirable anti-peg antibodies in a patient
|
|
WO2022064035A1
(en)
|
2020-09-28 |
2022-03-31 |
Ascendis Pharma Bone Diseases A/S |
Improvement of physical and mental well-being of patients with hypoparathyroidism
|
|
KR20230124637A
(ko)
|
2020-12-22 |
2023-08-25 |
엑스엘-프로테인 게엠베하 |
구조적으로 무질서한 서열에 대해 특이적인 항체
|
|
CN112843222B
(zh)
*
|
2021-01-21 |
2023-01-31 |
暨南大学 |
Ankrd22蛋白在制备治疗或延缓自身免疫性疾病的产品中的应用
|
|
JP2024514095A
(ja)
|
2021-04-01 |
2024-03-28 |
アセンディス ファーマ エー／エス |
炎症によって誘発される疾患を治療するための長時間作用型成長ホルモンの使用
|
|
IL311539A
(en)
|
2021-09-22 |
2024-05-01 |
Ascendis Pharma Bone Diseases As |
Long-acting pth compound treatments
|
|
WO2023110758A1
(en)
|
2021-12-13 |
2023-06-22 |
Ascendis Pharma Growth Disorders A/S |
Effective doses of cnp conjugates
|
|
EP4529454A1
(en)
|
2022-05-23 |
2025-04-02 |
Ascendis Pharma Growth Disorders A/S |
Liquid pharmaceutical formulations of cnp compounds
|
|
WO2023234416A1
(ja)
|
2022-06-02 |
2023-12-07 |
味の素株式会社 |
親和性物質、化合物、抗体およびそれらの塩
|
|
CN115927347B
(zh)
*
|
2022-10-14 |
2026-01-16 |
杭州佰辰医学检验所有限公司 |
特异性结合利培酮的核酸适配体及衍生物、应用、试剂盒
|
|
JP2025537527A
(ja)
|
2022-11-02 |
2025-11-18 |
アセンディス ファーマ ボーン ディジージズ エー／エス |
２つのｐｔｈ化合物を含むｐｔｈ治療レジメン
|
|
WO2024104922A1
(en)
|
2022-11-14 |
2024-05-23 |
Ascendis Pharma Growth Disorders A/S |
Method of improving skeletal muscle function
|
|
GB202218084D0
(en)
|
2022-12-01 |
2023-01-18 |
Volution Immuno Pharmaceuticals Sa |
Fusion proteins
|
|
AU2024240722A1
(en)
|
2023-03-20 |
2025-09-18 |
Ascendis Pharma Growth Disorders A/S |
Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
|
|
IL326658A
(en)
|
2023-09-04 |
2026-04-01 |
Ascendis Pharma Bone Diseases As |
PTH treatment in chronic kidney disease
|
|
WO2025088193A1
(en)
|
2023-10-27 |
2025-05-01 |
Xl-Protein Gmbh |
Methods for efficient recombinant production of polypeptides
|
|
WO2025088192A1
(en)
|
2023-10-27 |
2025-05-01 |
Xl-Protein Gmbh |
Methods for the coupling of di(alkyl)amines to polypeptides
|
|
WO2025233381A1
(en)
|
2024-05-07 |
2025-11-13 |
Technische Universität München, in Vertretung des Freistaates Bayern |
Enzymes that eliminate pyrimidine and/or purine nucleosides for treating cancer
|
|
GB202408081D0
(en)
|
2024-06-06 |
2024-07-24 |
Volution Immuno Pharmaceuticals Sa |
Methods of removing impurities
|